Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa

Conventional treatment of inflammatory bowel disease (IBD) is based on the daily administration of high doses of immune-suppressant or anti-inflammatory drugs, often complicated by serious adverse effects. Thus, a carrier system that delivers the drug specifically to the inflamed intestinal regions...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of controlled release 2012-07, Vol.161 (2), p.235-246
Hauptverfasser:	Collnot, Eva-Maria, Ali, Hussain, Lehr, Claus-Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	adverse effects Animals anti-inflammatory agents Anti-Inflammatory Agents - administration & dosage Antibodies Antiinflammatory agents Biological Products - administration & dosage biopharmaceuticals Controlled release Crohn's disease drug carriers Drug Carriers - administration & dosage Drug delivery Humans Immunomodulation immunomodulators Immunosuppressive agents Inflammation inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - pathology intestinal mucosa Intestinal Mucosa - pathology Intestine macrophages Models, Animal Mucosa mucus Nanomedicine Nanoparticle Nanoparticles - administration & dosage Nucleotides - administration & dosage Oral Pharmaceuticals Polymers - administration & dosage Side effects tumor necrosis factor-alpha Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!